Metal–Organic Frameworks as Drug Delivery Platforms for Ocular Therapeutics

Please use this identifier to cite or link to this item: http://hdl.handle.net/10045/86928
Información del item - Informació de l'item - Item information
Title: Metal–Organic Frameworks as Drug Delivery Platforms for Ocular Therapeutics
Authors: Gandara-Loe, Jesús | Ortuño Lizarán, Isabel | Fernández Sánchez, Laura | Alió, Jorge L. | Cuenca, Nicolás | Vega Estrada, Alfredo | Silvestre-Albero, Joaquín
Research Group/s: Materiales Avanzados | Neurobiología del Sistema Visual y Terapia de Enfermedades Neurodegenerativas (NEUROVIS)
Center, Department or Service: Universidad de Alicante. Departamento de Química Inorgánica | Universidad de Alicante. Departamento de Fisiología, Genética y Microbiología | Universidad de Alicante. Departamento de Óptica, Farmacología y Anatomía | Universidad de Alicante. Instituto Universitario de Materiales
Keywords: MOFs | Amorphization | Glaucoma treatment | Drug delivery | Ocular therapeutics
Knowledge Area: Química Inorgánica | Fisiología | Farmacología | Biología Celular
Issue Date: 18-Dec-2018
Publisher: American Chemical Society
Citation: ACS Applied Materials & Interfaces. 2019, 11(2): 1924-1931. doi:10.1021/acsami.8b20222
Abstract: Metal–organic frameworks (MOFs) have been evaluated as potential nanocarriers for intraocular incorporation of brimonidine tartrate to treat chronic glaucoma. Experimental results show that UiO-67 and MIL-100 (Fe) exhibit the highest loading capacity with values up to 50–60 wt %, whereas the performance is quite limited for MOFs with narrow cavities (below 0.8 nm, for example, UiO-66 and HKUST-1). The large loading capacity in UiO-67 is accompanied by an irreversible structural amorphization in aqueous and physiological media that promotes extended release kinetics above 12 days. Compared to the traditional drawbacks associated with the sudden release of the commercial drugs (e.g., ALPHAGAN), these results anticipate UiO-67 as a potential nanocarrier for drug delivery in intraocular therapeutics. These promising results are further supported by cytotoxicity tests using retinal photoreceptor cells (661W). Toxicity of these structures (including the metal nodes and organic ligands) for retinal cells is rather low for all samples evaluated, except for HKUST-1.
Sponsor: Authors would like to acknowledge the financial support from MINECO (MAT2016-80285-p), GV (PROMETEOII/2014/004), and H2020 (MSCA-RISE-2016/NanoMed Project). J.G.-L. acknowledges GV (GRISOLIAP/2016/089) for the research contract. N.C. acknowledges the financial support from MINECO (MINECO-FEDER-BFU2015-67139-R), ISCIII (RETICS-FEDER RD16/0008/0016), and GV (Prometeo 2016/158). I.O.-L. acknowledges Ministerio de Educación, Spain (FPU 14/03166).
URI: http://hdl.handle.net/10045/86928
ISSN: 1944-8244 (Print) | 1944-8252 (Online)
DOI: 10.1021/acsami.8b20222
Language: eng
Type: info:eu-repo/semantics/article
Rights: © 2018 American Chemical Society
Peer Review: si
Publisher version: https://doi.org/10.1021/acsami.8b20222
Appears in Collections:Research funded by the EU
INV - NEUROVIS - Artículos de Revistas
INV - LMA - Artículos de Revistas

Files in This Item:
Files in This Item:
File Description SizeFormat 
Thumbnail2019_Gandara-Loe_etal_ACSApplMaterInterfaces_final.pdfVersión final (acceso restringido)935,54 kBAdobe PDFOpen    Request a copy
Thumbnail2019_Gandara-Loe_etal_ACSApplMaterInterfaces_accepted.pdfAccepted Manuscript (acceso abierto)312,58 kBAdobe PDFOpen Preview


Items in RUA are protected by copyright, with all rights reserved, unless otherwise indicated.